Form 4: IN8BIO Director Brandt Exercises and Acquires Shares Through Warrant Amendments
SEC Form 4
Director Peter C. Brandt exercised warrants and acquired shares of IN8BIO, INC. following amendments to the warrant terms.
Summary
- Peter C. Brandt, a director of IN8BIO, INC., reported changes in beneficial ownership.
- On April 27, 2025, Brandt acquired 81,967 shares of common stock through the exercise of warrants at a price of $0.1844.
- These warrants were amended, resulting in the deemed cancellation of old warrants and the grant of replacement warrants.
- The exercise price of Series A warrants was reduced from $0.45 to $0.1844 per share, and the expiration date was amended to May 2, 2025.
- Similarly, the exercise price of Series B warrants was reduced from $1.50 to $0.1844 per share, with the expiration date also amended to May 2, 2025.
- Following these transactions, Brandt directly owns 681,538 shares of common stock and indirectly owns 105,290 shares through The Peter C. Brandt 2020-4 GRAT.
Sentiment
Score: 6
Explanation: Neutral sentiment as it primarily reports transactions related to warrant exercises and amendments, without expressing strong positive or negative views.
Positives
- Director Brandt's exercise of warrants and acquisition of shares could be interpreted as a sign of confidence in the company's future prospects.
Risks
- The warrant amendments and subsequent exercises could potentially dilute existing shareholders' equity.
Industry Context
This type of insider activity is common in publicly traded companies, especially those in the biotechnology sector where stock options and warrants are frequently used as compensation.
Comparison to Industry Standards
- Warrant exercises and amendments are a common practice in the biotech industry, often used to incentivize executives and raise capital.
- Companies like Juno Therapeutics and Kite Pharma have used similar strategies in the past.
- The impact of these transactions on shareholder value depends on the specific terms and the company's overall performance.
Stakeholder Impact
- Shareholders may experience dilution due to the exercise of warrants.
- The transactions could influence investor perception of the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 2023-12-13 | Original grant date of warrants at $1.22 per unit, each unit consisting of one share of common stock, one Series A warrant and one Series B warrant. |
| 2024-10-04 | Series A warrant amended with an exercise price of $0.45 per share and expiration date of October 4, 2025. |
| 2025-04-27 | Warrant exercise price reduced to $0.1844 per share and warrant expiration date amended to May 2, 2025. |
| 2025-04-30 | Director Brandt exercises warrants and acquires shares. |
| 2025-05-02 | Amended expiration date for Series A and Series B warrants. |
| 2025-05-07 | Date of filing the SEC Form 4. |
| 2025-10-04 | Original expiration date of Series A warrants. |
| 2028-12-13 | Original expiration date of Series B warrants. |
Keywords
IN8BIO, Brandt, warrant, exercise, director, shares, beneficial ownership, amendment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.